
Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Drugs In Development, 2022, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.
Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 4, 11, 2, 2, 13, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 1 molecules, respectively.
Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Drugs In Development, 2022, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.
Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 4, 11, 2, 2, 13, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 1 molecules, respectively.
Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
134 Pages
- Introduction
- Global Markets Direct Report Coverage
- Epidermolysis Bullosa – Overview
- Epidermolysis Bullosa – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Epidermolysis Bullosa – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Epidermolysis Bullosa – Companies Involved in Therapeutics Development
- Abeona Therapeutics Inc
- Aegle Therapeutics Corp
- Almirall SA
- Amniotics AB
- Amryt Pharma Plc
- Anterogen Co Ltd
- Avicanna Inc
- Berg LLC
- Biomendics LLC
- Branca Bunus Ltd
- Carocell Bio Ltd
- Castle Creek Biosciences Inc
- Celularity Inc
- Constant Therapeutics LLC
- CSA Biotechnologies LLC
- Daewoong Pharmaceutical Co Ltd
- Eloxx Pharmaceuticals Inc
- Energenesis Biomedical Co Ltd
- FIBRX Derm Inc
- Holostem Terapie Avanzate SRL
- Immusoft Corp
- InMed Pharmaceuticals Inc
- Kangstem Biotech Co Ltd
- Krystal Biotech Inc
- LambdaGen Therapeutics
- Mariposa Therapeutics Ltd
- Onconova Therapeutics Inc
- OTR3 SAS
- Palvella Therapeutics LLC
- Panag Pharma Inc
- Phoenix Tissue Repair Inc
- Quoin Pharmaceuticals Ltd
- RegeneRx Biopharmaceuticals Inc
- Relief Therapeutics Holding AG
- RHEACELL GmbH & Co KG
- Shionogi & Co Ltd
- StemRIM Inc
- Therapicon Srl
- TWi Biotechnology Inc
- Vera Therapeutics Inc
- Wings Therapeutics
- Epidermolysis Bullosa – Drug Profiles
- AC-203 – Drug Profile
- AGLE-102 – Drug Profile
- AGLE-103 – Drug Profile
- Amesanar – Drug Profile
- AP-103 – Drug Profile
- APRTD-011 – Drug Profile
- AVCN-583601 – Drug Profile
- beremagene geperpavec – Drug Profile
- birch triterpenes – Drug Profile
- BrB-101 – Drug Profile
- cannabinol – Drug Profile
- CL-2020 – Drug Profile
- CSA-144 – Drug Profile
- Cutistem – Drug Profile
- dabocemagene autoficel – Drug Profile
- diacerein – Drug Profile
- DWP-8181 – Drug Profile
- ENERGIF-703 – Drug Profile
- Gene Therapy for Epidermolysis Bullosa – Drug Profile
- Gene therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) – Drug Profile
- Gene Therapy to Activate COL7A1 for Epidermolysis Bullosa – Drug Profile
- Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa – Drug Profile
- Gene Therapy to Target COL7A1 for Recessive Dystrophic Epidermolysis Bullosa – Drug Profile
- hr-decorin – Drug Profile
- ISN-001 – Drug Profile
- JEL-1103 – Drug Profile
- KB-107 – Drug Profile
- KB-407 – Drug Profile
- Oligonucleotides to Activate COL7A1 for Epidermolysis Bullosa – Drug Profile
- PDA-002 – Drug Profile
- PJ-5 – Drug Profile
- Polymers for Epidermolysis Bullosa – Drug Profile
- PPP-004 – Drug Profile
- prademagene zamikeracel – Drug Profile
- PTR-01 – Drug Profile
- QRX-004 – Drug Profile
- QRX-323 – Drug Profile
- QRX-333 – Drug Profile
- redasemtide trifluoroacetate – Drug Profile
- RGN-137 – Drug Profile
- rigosertib sodium – Drug Profile
- sirolimus – Drug Profile
- Small Molecules to Inhibit Nrf2 for Epidermolysis Bullosa – Drug Profile
- Stem Cell Therapy for Epidermolysis Bullosa – Drug Profile
- Tolasure – Drug Profile
- TRIDs4DEB – Drug Profile
- TXA-127 – Drug Profile
- ubidecarenone – Drug Profile
- ZKN-013 – Drug Profile
- Epidermolysis Bullosa – Dormant Projects
- Epidermolysis Bullosa – Discontinued Products
- Epidermolysis Bullosa – Product Development Milestones
- Featured News & Press Releases
- Jul 26, 2022: InMed enrols first adolescent in Phase II epidermolysis bullosa trial
- Jun 22, 2022: Krystal Biotech submits biologics license application to U.S. FDA seeking approval of B-VEC for the treatment of patients with dystrophic epidermolysis bullosa
- May 23, 2022: Phoenix Tissue Repair report positive Phase II epidermolysis bullosa drug trial data
- May 19, 2022: Krystal Biotech to present additional data on B-VEC from the GEM-3 Phase 3 study at the Society for Investigative Dermatology Annual Meeting
- May 18, 2022: Tetra Bio-Pharma receives EMA Orphan Drug Designation for a novel topical therapeutic containing CBD
- Apr 11, 2022: Krystal Biotech announces home dosing in B-VEC open label extension study
- Mar 28, 2022: Krystal Biotech announces publication of phase 1 and 2 clinical trial (GEM 1/2 Study) of beremagene geperpavec (B-VEC) data in Nature Medicine
- Mar 26, 2022: New GEM-3 phase 3 results for B-VEC presented at 2022 American Academy of Dermatology Annual Meeting
- Mar 18, 2022: Krystal Biotech to present at 2022 American Academy of Dermatology annual meeting
- Mar 14, 2022: Abeona Therapeutics achieves target enrollment in pivotal phase 3 VIITAL study of EB-101 in RDEB
- Nov 30, 2021: Krystal’s dystrophic EB gene therapy trial meets primary goal
- Nov 18, 2021: Abeona Therapeutics announces support of EB research partnership's venture into cures event to raise awareness for education and research of epidermolysis bullosa
- Oct 26, 2021: Krystal Biotech announces completion of the GEM-3 pivotal phase 3 study evaluating B-VEC for the treatment of dystrophic epidermolysis bullosa
- Oct 21, 2021: Castle Creek Biosciences awarded FDA Orphan products development grant to support DeFi-RDEB, a pivotal phase 3 study of FCX-007 investigational gene therapy for recessive dystrophic epidermolysis bullosa
- Sep 30, 2021: InMed Pharmaceuticals announces commencement of phase 2 clinical trial investigating cannabinol (CBN), a rare cannabinoid, in the treatment of epidermolysis bullosa
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Epidermolysis Bullosa, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Universities/Institutes, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Companies, 2022 (Contd..2)
- Table 8: Products under Development by Universities/Institutes, 2022
- Table 9: Number of Products by Stage and Target, 2022
- Table 10: Number of Products by Stage and Mechanism of Action, 2022
- Table 11: Number of Products by Stage and Route of Administration, 2022
- Table 12: Number of Products by Stage and Molecule Type, 2022
- Table 13: Epidermolysis Bullosa – Pipeline by Abeona Therapeutics Inc, 2022
- Table 14: Epidermolysis Bullosa – Pipeline by Aegle Therapeutics Corp, 2022
- Table 15: Epidermolysis Bullosa – Pipeline by Almirall SA, 2022
- Table 16: Epidermolysis Bullosa – Pipeline by Amniotics AB, 2022
- Table 17: Epidermolysis Bullosa – Pipeline by Amryt Pharma Plc, 2022
- Table 18: Epidermolysis Bullosa – Pipeline by Anterogen Co Ltd, 2022
- Table 19: Epidermolysis Bullosa – Pipeline by Avicanna Inc, 2022
- Table 20: Epidermolysis Bullosa – Pipeline by Berg LLC, 2022
- Table 21: Epidermolysis Bullosa – Pipeline by Biomendics LLC, 2022
- Table 22: Epidermolysis Bullosa – Pipeline by Branca Bunus Ltd, 2022
- Table 23: Epidermolysis Bullosa – Pipeline by Carocell Bio Ltd, 2022
- Table 24: Epidermolysis Bullosa – Pipeline by Castle Creek Biosciences Inc, 2022
- Table 25: Epidermolysis Bullosa – Pipeline by Celularity Inc, 2022
- Table 26: Epidermolysis Bullosa – Pipeline by Constant Therapeutics LLC, 2022
- Table 27: Epidermolysis Bullosa – Pipeline by CSA Biotechnologies LLC, 2022
- Table 28: Epidermolysis Bullosa – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Table 29: Epidermolysis Bullosa – Pipeline by Eloxx Pharmaceuticals Inc, 2022
- Table 30: Epidermolysis Bullosa – Pipeline by Energenesis Biomedical Co Ltd, 2022
- Table 31: Epidermolysis Bullosa – Pipeline by FIBRX Derm Inc, 2022
- Table 32: Epidermolysis Bullosa – Pipeline by Holostem Terapie Avanzate SRL, 2022
- Table 33: Epidermolysis Bullosa – Pipeline by Immusoft Corp, 2022
- Table 34: Epidermolysis Bullosa – Pipeline by InMed Pharmaceuticals Inc, 2022
- Table 35: Epidermolysis Bullosa – Pipeline by Kangstem Biotech Co Ltd, 2022
- Table 36: Epidermolysis Bullosa – Pipeline by Krystal Biotech Inc, 2022
- Table 37: Epidermolysis Bullosa – Pipeline by LambdaGen Therapeutics, 2022
- Table 38: Epidermolysis Bullosa – Pipeline by Mariposa Therapeutics Ltd, 2022
- Table 39: Epidermolysis Bullosa – Pipeline by Onconova Therapeutics Inc, 2022
- Table 40: Epidermolysis Bullosa – Pipeline by OTR3 SAS, 2022
- Table 41: Epidermolysis Bullosa – Pipeline by Palvella Therapeutics LLC, 2022
- Table 42: Epidermolysis Bullosa – Pipeline by Panag Pharma Inc, 2022
- Table 43: Epidermolysis Bullosa – Pipeline by Phoenix Tissue Repair Inc, 2022
- Table 44: Epidermolysis Bullosa – Pipeline by Quoin Pharmaceuticals Ltd, 2022
- Table 45: Epidermolysis Bullosa – Pipeline by RegeneRx Biopharmaceuticals Inc, 2022
- Table 46: Epidermolysis Bullosa – Pipeline by Relief Therapeutics Holding AG, 2022
- Table 47: Epidermolysis Bullosa – Pipeline by RHEACELL GmbH & Co KG, 2022
- Table 48: Epidermolysis Bullosa – Pipeline by Shionogi & Co Ltd, 2022
- Table 49: Epidermolysis Bullosa – Pipeline by StemRIM Inc, 2022
- Table 50: Epidermolysis Bullosa – Pipeline by Therapicon Srl, 2022
- Table 51: Epidermolysis Bullosa – Pipeline by TWi Biotechnology Inc, 2022
- Table 52: Epidermolysis Bullosa – Pipeline by Vera Therapeutics Inc, 2022
- Table 53: Epidermolysis Bullosa – Pipeline by Wings Therapeutics, 2022
- Table 54: Epidermolysis Bullosa – Dormant Projects, 2022
- Table 55: Epidermolysis Bullosa – Dormant Projects, 2022 (Contd..1)
- Table 56: Epidermolysis Bullosa – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Epidermolysis Bullosa, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.